Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 16NETWORK 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Other 1

Conditions

Prostatic Neoplasms 2Urinary Incontinence 1Sexual Dysfunction, Physiological 1Erectile Dysfunction 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Tadalafil × Clear all
NCT07576335 2026-05-08

ROBOPREP

Surgical Outcomes Research Centre (SOuRCe)

Phase 2 Not yet recruiting
64 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Urinary Incontinence

NCT00931528 2018-02-14

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Radiation Therapy Oncology Group

Phase 3 Completed
242 enrolled 13 charts
GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡